Permanent 100% Antimicrobial Medical Plastic

描述（由申请人提供）：永久性100%抗菌医用塑料对抗感染是整个医学界的主要目标之一，因为与感染患者的护理相关的指数成本。为减少医疗机构内患者交叉感染所带来的感染而进行的技术创新，可以对医学界在资金和人命方面产生重大影响。大约5%至10%的住院患者在住院期间会接触到某种形式的感染。据估计，医院每年花费超过300亿美元，医院感染可能导致10万多人丧生。统计数据显示，个人卫生（主要是用抗菌肥皂洗手）的发生频率不够高，不足以防止医疗机构每年承受300亿美元的支出。不幸的是，只有0.1-1.0%的可浸出抗菌添加剂的医疗产品只能提供暂时的抗菌作用，因为通过清洗或擦拭医疗产品表面可以很容易地去除杀菌剂。布莱顿发展与美国国立卫生研究院支持开发了一种100%永久性抗菌塑料，可用于医疗保健社区的众多医疗产品。在第二阶段，我们希望重点开发这一发现作为永久性100%抗菌材料的可行性，并展示其在医疗环境中对抗感染的优势。Brighton Development将生成所需的数据，以便在EPA获得100%抗菌产品的注册，并随后将这些产品提供给医疗保健社区。该项目的目标与NIH消除HAI（医疗保健相关感染）的首要任务之一保持一致，这在美元和人类生命方面都有巨大的影响。

DESCRIPTION (provided by applicant): PERMANENT 100% ANTIMICROBIAL MEDICAL PLASTIC Combating infections is one of the major goals of the entire medical community due to the exponential cost associated with care of an infected patient. Technology innovations to reduce infection brought about by cross-contamination of patients staying in healthcare facilities can have major impact to the medical community in terms of both dollars and human lives. Approximately 5% to 10% of all patients entering a hospital will contact some form of infection during their stay at the healthcare facility. It is estimated that hospitals spend over $30 billion annually and over 100,000 lives can be lost as a result of nosocomial infections. Statistics show that personal hygiene consisting mainly of hand washing with antimicrobial soaps does not occur frequently enough to prevent the $30 billion dollar expenditure that healthcare facilities endure on an annual basis. Unfortunately, medical products containing only 0.1-1.0% of leachable antimicrobial additives only provide temporary antimicrobial action because the biocidal agent can be easily removed by washing or wiping the surface of the medical product. Brighton Development has developed with NIH support a 100% permanent antimicrobial plastic that can be used in numerous medical products found in the healthcare community. In Phase II, we would like to focus on exploiting the feasibility of this discovery as a permanent 100% antimicrobial material and demonstrate its advantages in combating infection in the healthcare environment. Brighton Development will generate the required data to obtain registration of the 100% antimicrobial products with the EPA and subsequently provide these products to the healthcare community. The goals of this project are in alignment with one of NIH top priorities of HAI elimination (Healthcare-associated Infections) that has dramatic impact in terms of both dollars and human lives. PUBLIC HEALTH RELEVANCE: This proposal is aimed at developing permanent 100% antimicrobial medical plastic products that can be used to reduce the billions of dollars spent annually by healthcare facilities to combat patient infections. Statistics show that the magnitude of this problem affects from 5-10% of all people entering the hospital and accounts for annual expenditures by the medical community of over 30 billion dollars even with documented frequencies of antimicrobial hand washing by hospital staff. A truly durable 100% antimicrobial plastic material developed in Phase I with NIH support could find numerous uses in medical products throughout healthcare facilities. As a part of the Phase II, the 100% antimicrobial products will be registered with the EPA and subsequently provided to the healthcare community. The goals of this project are in alignment with one of NIH top priorities of HAI elimination (Healthcare-associated Infections) that has dramatic impact in terms of both dollars and human lives.